**TABLE 1. ACTIVE CLINICAL TRIALS COMBINATORIAL STRATEGIES**

An organised summary of ongoing clinical trials on DCs-based cancer vaccines with combination strategies

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Study ID | Therapeutic Strategy | Condition/Disease | Phase | Status |
| NCT01067287 | CT-011 alone, or  plus DC fusion vaccine after ASCT | MM | II | Active, not recruiting |
| NCT02528682 | MiHA-loaded PD-L-silenced DC Vaccination after allo-SCT | Hematological Malignancies | I/II | Completed |
| NCT01096602 | Blockade of PD-1 plus DC/AML Vaccine after Chemotherapy | AML | II | Active, not recruiting |
| NCT03035331 | Intratumorally DC vaccine After Cryoablation and Pembrolizumab | LNH | I/II | Active, not recruiting |
| NCT03325101 | Intratumorally Autologous DC vaccine after Cryoablation plus Pembrolizumab | Melanoma | I/II | Active, not recruiting |
| NCT02677155 | Sequential Intranodal Immunotherapy (SIIT) plus Pembrolizumab | FLC | II | Completed |
| NCT05631886 | Intratumorally Autologous DC vaccine plus Cryoablation and Pembrolizumab | LNH | I/II | Active, not recruiting |

**AML:** Acute Myeloid Leukemia**; MM:** MultipleMyeloma.